# EDGAR Filing Document

**Accession Number:** 0001574565
**File Stem:** 0001178913-26-002074
**Filing Date:** 2026-4
**Character Count:** 2784
**Document Hash:** 2e3b145c019626a9a64e908720596836
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-26-002074.hdr.sgml**: 20260513

**ACCESSION NUMBER**: 0001178913-26-002074

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260413

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Evogene Ltd.
- **CENTRAL INDEX KEY:** 0001574565
- **STANDARD INDUSTRIAL CLASSIFICATION:** AGRICULTURE CHEMICALS [2870]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 13 GAD FEINSTEIN STREET
- **STREET 2:** PARK REHOVOT
- **CITY:** REHOVOT
- **STATE:** L3
- **ZIP:** 7638517
- **BUSINESS PHONE:** 97289311900

**MAIL ADDRESS:**
- **STREET 1:** 13 GAD FEINSTEIN STREET
- **STREET 2:** PARK REHOVOT
- **CITY:** REHOVOT
- **STATE:** L3
- **ZIP:** 7638517

------

![](image0.jpg)

Evogene Ltd.

13 Gad Feinstein Street, Park Rehovot

Rehovot 7638517, Israel

April 13, 2026

<u>VIA EDGAR</u>

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Nicholas O'Leary

---

| | |
|:---|:---|
| **Re:** | **Evogene Ltd. (the "Company")** |
|  | **Registration Statement on Form F-3** |
|  | **Filed March 26, 2026** |
|  | **File No. 333-294650** |

---

<br> Dear Mr. O'Leary:

Pursuant to Rule 461(a) under the Securities Act of 1933, as amended (the "**Act**"), the Company hereby respectfully requests that the effective date of the Company's Registration Statement on Form F-3 (File No. 333-294650) be accelerated by the Securities and Exchange Commission to 9:00 a.m., Eastern Daylight Time, on April 15, 2026 or as soon as possible thereafter. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

We request that we be notified of such effectiveness by email to Jonathan M. Nathan, Adv., of Meitar Law Offices, at <u>jonathann@meitar.com</u>. Please also contact Mr. Nathan if you have any other questions or concerns regarding this matter.

*[Signature page follows]*

------

---

| | | |
|:---|:---|:---|
| Sincerely,<br>EVOGENE LTD. | Sincerely,<br>EVOGENE LTD. | Sincerely,<br>EVOGENE LTD. |
| By: | /s/ Ofer Haviv | /s/ Ofer Haviv |
|  | Name: | Ofer Haviv |
|  | Title: | Chief Executive Officer and President |

---

---

| | |
|:---|:---|
| cc: | *Polina Ravzin, VP Finance*, *Evogene Ltd.* |
|  | Howard E. Berkenblit, Esq., Sullivan & Worcester LLP<br> Brendan O'Brien, Esq., Sullivan & Worcester LLP<br>|
|  | Mike Rimon, Adv., *Meitar Law Offices*<br> Jonathan M. Nathan, Adv., *Meitar Law Offices*<br> Elad Ziv, Adv., *Meitar Law Offices* |

---

------